Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Amgen has been struggling to grow its revenue at a good clip organically. The company's pipeline and a recent acquisition should help it improve. The biotech is an excellent stock for income ...
Novartis plans to cut as many as 680 jobs in development, Sanofi's pipeline reprioritization project will result in layoffs.
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of ...
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ...
Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol ...
Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar ...